Eejung Kim

机构：Neuroendocrine Tumor Research Foundation, Dana-Farber Cancer Institute · ORCID：0000-0003-0381-0992

发表论文 90 篇 · 总被引 1629 次 · h-index 12

代表论文

• Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer (2024 · Cancer Cell · 被引 129)
• A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors (2025 · Science · 被引 50)
• Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity (2024 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 9)
• Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer (2024 · American Society of Clinical Oncology Educational Book · 被引 8)
• Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer (2026 · Nature Medicine · 被引 3)
• Deep-Transfer-Learning–Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Cancer (2024 · JCO Clinical Cancer Informatics · 被引 3)